Furthermore, Dr. Ron Garren thinks that there is a pretty good chance that their ovarian cancer drug will be approved by the EMEA, especially if their Phase III is up and running by the time of approval. (I realize that the Doxil shortage is putting a crimp in their plans.)
I don't have the scientific knowledge nor the regulatory affairs knowledge to make a judgment on that.
On their last CC, ECYT said that they would be initiating a randomized Phase II trial with EC145 and EC20 in non small-cell lung cancer.
It seems like they deserve more than a zero enterprise value.
Market Data 
Markets 
AI
